Elsbernd Brian

Chief Compliance Officer Brian Elsbernd sells 40,000 CPRX shares at $22.70, retaining 231,039 shares; stock up 9.0% in 30 days.

Elsbernd sold 40,000 shares (40.0K shares) at $22.70 on 2025-11-12, representing a -14.8% reduction from his 271,039 pre-transaction holdings. At the time of sale, CPRX had gained 9.0% over the prior 30 days and 14.6% over 90 days, contextualizing the sale against a period of upward price momentum. His same-ticker trade history at CPRX shows 5 prior sells, with measurable 90-day outcomes on 2 trades: both resulted in positive 90-day returns (+7.4% and +8.8%), indicating that his prior CPRX sales were not well-timed (the stock rose after he sold). The company's latest quarter generated $148.4M in revenue with $52.8M net income and 23.5% annual revenue growth, accompanied by a P/E of 13.10, suggesting moderate valuation relative to profitability. The discretionary nature and quantum of this sale warrant monitoring against any forward signals regarding operational or market outlook.

Chief Compliance Officer Brian Elsbernd sells 30,000 CPRX shares at $20.30; stock down 25.0% from 52-week high.

Brian Elsbernd, Chief Compliance/Legal Officer, sold 30,000 shares (10.0% of pre-transaction holdings) at $20.30 on 2025-09-08, following two consecutive sales on 2025-09-04 and 2025-09-03. The stock currently trades at $19.74, which is 25.0% below its 52-week high of $26.31 and down 18.7% over the past 90 days. His prior sales at CPRX have not demonstrated prescient timing: 2 measurable outcomes from March 2025 show positive 90-day returns (+7.4% and +8.8%), indicating the stock rose after those sales. Against his cross-ticker track record, his 90-day well-timed rate stands at 0.00%, and average 90-day returns after his open-market sells have been +8.2%. The company's fundamentals remain solid—$146.6M quarterly revenue, $52.1M net income, 23.5% annual revenue growth, and a P/E of 11.61—indicating no obvious operational stress. The concentration of three sales within five days warrants monitoring, though the lack of measurable outcomes for the two most recent sales limits pattern interpretation.

Chief Compliance Officer Elsbernd sold 50,000 shares (50.0K shares) for $987,200.00 across two trades; stock down 21.6% in 90 days.

Brian Elsbernd, Chief Compliance/Legal Officer at Catalyst Pharmaceuticals, executed 2 separate sales totaling 50,000 shares (50.0K shares) for $987,200.00 on 2025-09-03 and 2025-09-04, reducing his holdings by 21.0% from 238,564 shares to 188,564 shares. The stock has declined 21.6% over the 90-day period and 6.9% over 30 days, trading 22.9% below its 52-week high of $26.31. The company shows solid fundamentals with $146.6M in latest quarterly revenue, $52.1M net income, 23.5% annual revenue growth, and an 11.94 P/E ratio. While his prior 2 sales at this ticker generated positive 90-day returns (averaging +8.1%), his cross-ticker track record shows 0.00% well-timed rate on sells, indicating his historical sales have not generally preceded further declines—a pattern that differs from the current post-sale weakness at this specific company.

CCO Brian Elsbernd sells 62,975 CPRX shares across 2 transactions for $1,446,932.75; retains 188,564 shares post-sale

Brian Elsbernd, Chief Compliance/Legal Officer at Catalyst Pharmaceuticals, executed 2 separate sales totaling 62,975 shares for $1,446,932.75 on 2025-03-03 at blended average price $22.98, reducing his holdings by 25.0% from 251,539 to 188,564 shares. The transactions occurred near the stock's 52-week high ($23.96), with current price at $21.89, placing the execution 8.6% below the year's peak. The company's fundamentals show strong momentum: latest quarterly revenue of $128,695,000.00, net income of $43,884,000.00, and annual revenue growth of +23.5%, alongside a reasonable valuation (P/E 11.28). The magnitude and timing of this sale by a senior legal and compliance officer merit monitoring, particularly given the company's solid financial trajectory and recent strength in stock price.